Table 5:
Adverse Events with 5-ALA in Comparison to Standard Care
| Systematic Review Author, Year | Number of Included Studies | Adverse Outcome | 5-ALA (%) | Standard Care (%) |
|---|---|---|---|---|
| Jenkinson et al, 201845 | 1 | Overall adverse events | 58.7 | 57.8 |
| Neurological adverse events | 42.8 | 44.5 | ||
| Grades III and IVa | 7 | 5.2 | ||
| Significant neurological adverse eventsb | 12.4 | 11.6 | ||
| Deterioration in NIH Stroke Scale compared to baseline—48 hours | 26.2 | 14.5 | ||
| Deterioration in NIH Stroke Scale compared to baseline—7 days | 20.5 | 10.7 | ||
| Deterioration in NIH Stroke Scale compared to baseline—6 weeks | 17.1 | 11.3 | ||
| Deterioration in NIH Stroke Scale compared to baseline—3 months | 19.6 | 18.6 |
Abbreviations: 5-ALA, 5-aminolevulinic acid hydrochloride; NIH, National Institutes of Health.
a
According to the Common Toxicity Criteria (data obtained from the primary Stummer et al article for further clarification).50
b
Defined as aphasia, convulsions, grand mal seizure, hemiparesis, intracranial hypertension and stupor (data obtained from the primary Stummer et al50 article for further clarification)